BRCA1 and BRCA2 Mutation Management Guidelines

Introduction to Risk Management

The American College of Medical Genetics and Genomics and other guideline societies recommend that individuals with BRCA1 or BRCA2 mutations require intensive breast surveillance starting at age 25 with annual breast MRI, clinical breast examinations every 6-12 months, and should strongly consider risk-reducing bilateral salpingo-oophorectomy (RRSO) between ages 35-40 for BRCA1 carriers or after age 45 for BRCA2 carriers to reduce both ovarian and breast cancer mortality 1, 2.

Annual breast MRI beginning at age 25 demonstrates 77% sensitivity compared to only 36% for mammography in detecting breast cancers in BRCA carriers, as recommended by the National Comprehensive Cancer Network 1, 4.
Clinical breast examination every 6-12 months starting at age 25 or 10 years before the youngest breast cancer diagnosis in the family, whichever is earlier, is advised by the American Cancer Society 1, 2, 4.
Annual breast MRI and annual mammography starting at age 30 are recommended for comprehensive screening, according to the American College of Radiology 1, 2, 4.

BRCA1 carriers should consider RRSO between ages 35-40 after completion of childbearing, while BRCA2 carriers should consider RRSO after age 45, as suggested by the Society of Gynecologic Oncology 1, 3, 4.
RRSO reduces ovarian cancer risk by approximately 90% and breast cancer risk by approximately 50%, based on data from the American Society of Clinical Oncology 4.
Bilateral prophylactic mastectomy is the most effective method for reducing breast cancer risk in BRCA mutation carriers and can be considered starting at age 25, according to the American Society of Breast Surgeons 3, 4.

Breastfeeding when possible is recommended, as observational studies suggest reduced breast cancer risk among BRCA carriers, as noted by the American College of Obstetricians and Gynecologists 2, 3.
Maintaining regular exercise and healthy body weight, limiting alcohol consumption, and avoiding hormone replacement therapy (HRT) are also advised, based on guidelines from the American Heart Association and the National Institute on Alcohol Abuse and Alcoholism 2, 3.

Comprehensive counseling outlining screening options, risk-reducing surgeries, chemoprevention, and fertility preservation should be provided, emphasizing the early onset characteristics of BRCA-associated cancers and the limitations of ovarian cancer screening, as recommended by the National Society of Genetic Counselors 1, 2, 4.
Addressing quality of life and psychosocial impacts of intensive surveillance and risk-reducing interventions is crucial, according to the American Psychological Association 1, 2, 4.

Enrolling carriers in dedicated high-risk follow-up clinics when available provides coordinated multidisciplinary care, as suggested by the American College of Medical Genetics and Genomics 2, 3, 4.
Common pitfalls to avoid include delaying screening initiation beyond age 25, failing to discuss prophylactic mastectomy, underestimating the importance of lifestyle modifications, not addressing the psychological burden, and overlooking fertility preservation counseling, as highlighted by the Society of Gynecologic Oncology and the American Society of Clinical Oncology 2, 3, 4.